



BMT CTN 0401

Auto PBSCT for NHL with Bexxar vs Rituximab Conditioning

Objective

- 2 year progression-free survival after **autologous** hematopoietic stem cell transplantation comparing **Rituximab/BEAM vs Bexxar/BEAM** conditioning

Eligibility

- REAL classification DLBC NHL (> 50% diffuse component)
- Chemo-sensitive disease: at least a partial response to induction or salvage therapy
- Received ≤ 3 prior chemotherapy regimens (monoclonal antibodies and involved field XRT not counted)
- Age 18 - 80 years

TREATMENT SCHEMA

Chemosensitive patients following salvage chemotherapy

Chemotherapy
Rituximab
Collection of autologous HSCs

RANDOMIZATION

Bexxar (5mCi dosimetric dose Day -19, 75cGy total body therapeutic dose Day -12) BCNU (Day -6), VP-16 and Cytarabine (Day -5, -4, -3, -2), Melphalan (Day -1)

Autologous HCT

Rituximab (375mg/m², Day -19, Day -12) BCNU (Day -6), VP-16 and Cytarabine (Day -5, -4, -3, -2), Melphalan (Day -1)

Autologous HCT

To view the entire protocol, go to <http://www.bmtctn.net>
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0401>

This is a Phase III multi-center trial jointly sponsored by the NHLBI and NCI.